Treatment of a patient with end-stage renal disease with Rituximab: Pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis

American Journal of Hematology

Volumn 71, Issue 3, 2002, Pages 219-222

  Jillella, Anand P ^a   Dainer, Paul M ^a   Kallab, Andre M ^a   Ustun, Celalettin ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Follicular lymphoma; Hemodialysis; Low grade lymphoma; Renal failure; Rituximab; Tumor lysis

Indexed keywords

RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG ELIMINATION; HEMOCONCENTRATION; HEMODIALYSIS; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; LYMPHOMA; MALE; PHARMACOKINETICS; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KIDNEY FAILURE, CHRONIC; LYMPHOMA; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 0036830415     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10213     Document Type: Article

References (15)

1. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles T, Dallaire BK, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (Rituximab) anti CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-2195.
2. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles T, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's Lymphoma. J Clin Oncol 1997;15:3266-3274.
3. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998;92:1927-1932.
4. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Vams C. Treatment of patients with low-grade B-cell lymphoma with a combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276.
5. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19:389-397.
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
7. Castro M. Van Auken J, Sponzo R. Successful use of anti-CD20 monoclonal antibody, Rituximab, in patients with non-Hodgkin's lymphoma (NHL) and renal insufficiency [Abstract]. Proc Am Soc Clin Oncol 2001;20:233b.
8. Iacona I, Lazzarino M, Avanzini MA, Rupola M, Arcaini L, Astori C, Lunghi F, Orlandi E, Morra E, Zagonel V, Regazzi MB. Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 2000; 22:295-301.
9. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Association of serum Rituximab (IDEC-C2b8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001.
10. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, Varns C, Shuey S, Czuczman M, Lynch JW, Kolitz JE, Jain V. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655-661.
11. McKelvey EM, Yeoh HH, Schuster GA, Sharma B, Levin NW. Immunoglobulin and dextran losses during peritoneal dialysis. Arch Intern Med 1974;134:266-269.
12. Nath IVS, Sehgal S, Chugh KS, Sharma BK. Loss of immunoglobulins during peritoneal dialysis. J Assoc Phys Ind 1981;29:927-929.
13. Nakauchi H, Okumura K, Tango T. Immunoglobulin levels in patients on long-term hemodialysis. N Engl J Med 1981;305:172-173.
14. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of Rituximab in lymphoproliferative disorders; high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999;62:247-250.
15. Jensen M, Winkler U, Manzke O, Diehl V, Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Ann Hematol 1998;77:89-91.